House Rx

The Pharmacy Sitting in the Waiting Room

Imagine you've just been diagnosed with cancer. You leave your oncologist's office with a prescription for a specialty drug that costs thousands of dollars a month. Your doctor's nurse says the pharmacy will be in touch. Two weeks pass. You make phone calls. You navigate automated phone trees. You fax forms to an insurance company. Your medication still hasn't arrived.

That two-week gap - between diagnosis and first dose - is what House Rx was built to collapse. Not with a wellness app or a chatbot. With a pharmacy that lives inside the clinic itself.

Since 2021, the San Francisco company has been rolling out what it calls medically integrated dispensing (MID): a model where the pharmacist isn't at a call center in Phoenix, but down the hall from your oncologist, integrated into the same electronic health record, coordinating care in real time. The average fill time through House Rx's platform is 3.5 days. The industry average is 15.5 days.

The Problem Is Structural

Specialty drugs - biologics, oncology agents, rare disease treatments - account for over half of all US drug spending, dispensed to less than 2% of patients. These are the most complex, most expensive, most time-sensitive medications in the system. They're also the ones most likely to get stuck in administrative purgatory.

The existing model hands control to pharmacy benefit managers (PBMs) - large intermediaries like CVS Caremark, Express Scripts, and OptumRx that sit between the physician and the patient. PBMs process prior authorizations, coordinate insurance, and ship medications through mail-order facilities. The incentives, however, are not obviously aligned with getting patients their medication faster. They're aligned with managing cost at scale.

For a cancer patient starting chemotherapy, a two-week delay isn't an inconvenience. It's a clinical event.

Two People Who Had Seen This Before

Ogi Kavazovic and Tesh Khullar are not pharmacy outsiders with a disruption thesis. Both came from Flatiron Health, the oncology software company that built deeply into hundreds of cancer clinics before being acquired by Roche in 2018. They spent years watching what happens when physicians and pharmacists are on different systems, different timelines, different organizational charts. The friction wasn't incidental. It was baked in.

They left Flatiron with a specific bet: that the medically integrated dispensing model - where the clinic both treats and dispenses - could be made scalable with the right technology. The problem wasn't that MID was impossible. It's that building and running an in-house pharmacy requires significant operational infrastructure that most independent specialty clinics don't have.

House Rx provides that infrastructure.

The Platform: One Team, One System

The House Rx platform is built around a single thesis: the physician, pharmacist, nurse, and care coordinator should function as one clinical team, not as separate organizations that communicate by fax.

The technology integrates directly into a clinic's existing EHR system, letting prescribers collaborate with House Rx pharmacists within the same interface they already use for patient records. Prior authorizations, refill coordination, financial counseling, insurance navigation - all of it flows through one system rather than bouncing between phone calls and portals.

The Proof: Clinics, Patients, Numbers

House Rx now operates across 80 clinic sites in states including California, Washington, Virginia, Arizona, Pennsylvania, North Carolina, and Tennessee. It serves nearly 61,000 patients through a network of 1,000+ providers, primarily in oncology and rheumatology. The platform processes approximately $1.5 billion in specialty prescriptions annually, with the company projecting growth to $3 billion by end of 2026.

The outcome data is specific. Clinics using House Rx see 95% medication adherence against a 70% industry average. Total healthcare costs for patients managed through the platform run roughly 13% lower. Prescribers reclaim 20+ hours per week in administrative time - time previously consumed by prior authorization phone calls and refill follow-ups.

Patient satisfaction scores run 50% higher than comparable care. Time to first dose is four times faster.

Smart PA: The AI That Does the Paperwork

In April 2025, House Rx released Smart PA, its generative AI prior authorization tool - and the case it makes is almost absurdly direct. Prior authorization is a paperwork process that delays critical medications. The paperwork asks predictable questions. The answers already exist in the patient's EHR. The only reason a human was doing it is that no one had automated it yet.

Smart PA retrieves the payer's question set, pre-fills responses using patient records, generates a complete prior authorization response in approximately 15 seconds, and submits it in under 60 seconds. First-pass approval rate: 92%. The company says it automates 80% of PA workflows, and plans to expand AI coverage to 85% of all pharmacy software workflows including scheduling, prescription intake, and documentation.

That's not a stretch goal. It's a roadmap for what happens when the people building software actually understand what the software is supposed to replace.

The Funding Stack

In November 2025, House Rx closed a $55 million Series B led by New Enterprise Associates and Town Hall Ventures, bringing total funding to $100 million. NEA is one of the oldest and largest healthcare-focused venture firms in the US. Town Hall Ventures was co-founded by Andy Slavitt, who ran the Centers for Medicare and Medicaid Services under President Obama - a signal that the investors believe this isn't a niche play but a structural reordering of how specialty pharmacy works at the system level.

Earlier backers include Bessemer Venture Partners, First Round Capital, Character.vc, LRVHealth, and Silicon Valley Bank. The Series A in March 2022 was $30 million.

Why It Matters Tomorrow

Specialty pharmacy spending is growing faster than any other segment of US healthcare. The drugs are getting more expensive, more complex, and more dependent on adherence to work. The administrative infrastructure required to access them is not improving. If anything, prior authorization requirements have expanded substantially over the past decade.

House Rx's argument is not that PBMs will disappear. It's that for the subset of patients who are being treated at specialty clinics - oncology, rheumatology, rare disease - the medically integrated model produces measurably better outcomes at measurably lower cost. And that with the right technology, any specialty clinic can run it.

Named one of Time Magazine's Top HealthTech Companies of 2025, the company is approaching 280 employees and processing prescriptions at a pace that doubles its prior year volume. The waiting room where a patient once got their diagnosis and then waited two weeks for a drug to arrive - that's the room House Rx has its sights on. The pharmacist is already there. The software is what makes the difference.

Links & Resources

• ● houserx.com - Official website
• ● LinkedIn - house-rx
• ● Twitter/X - @TeamHouseRx
• ● Facebook - TeamHouseRx
• ● Series B Announcement - PR Newswire
• ● Smart PA Launch - PR Newswire
• ● CEO Interview - Slice of Healthcare Podcast
• ● CEO Interview - The Health Care Blog
• ● Coverage - HIT Consultant
• ● Coverage - MobiHealthNews